Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report  

作　　者：Mei-Hong Liu Yan-Xia Li Zhuo Liu 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,First Affiliated Hospital of Dalian Medical University,Dalian 116011,Liaoning Province,China

出　　处：《World Journal of Clinical Cases》2023年第5期1115-1121,共7页世界临床病例杂志

基　　金：Supported by the Foundation of Science and Technology Bureau of Dalian,No. 2021JJ13SN70。

摘　　要：BACKGROUND Combined small cell lung cancer(C-SCLC) is a special subtype of small cell lung cancer that is relatively rare, aggressive, and prone to early metastasis and has a poor prognosis. Currently, there are limited studies on C-SCLC, and there is no uniform standard treatment, especially for extensive C-SCLC, which still faces great challenges. In recent years, the development and progress of immunotherapy have provided more possibilities for the treatment of C-SCLC. We used immunotherapy combined with first-line chemotherapy to treat extensive-stage C-SCLC to explore its antitumor activity and safety.CASE SUMMARY We report a case of C-SCLC that presented early with adrenal, rib, and mediastinal lymph node metastases. The patient received carboplatin and etoposide with concurrent initiation of envafolimab. After 6 cycles of chemotherapy, the lung lesion was significantly reduced, and the comprehensive efficacy evaluation showed a partial response. No serious drug-related adverse events occurred during the treatment, and the drug regimen was well tolerated.CONCLUSION Envafolimab combined with carboplatin and etoposide in the treatment of extensive-stage C-SCLC has preliminary antitumor activity and good safety and tolerability.

关 键 词：Combined small cell lung cancer Envafolimab CARBOPLATIN ETOPOSIDE PROGNOSIS Case report 

分 类 号：R734.2[医药卫生—肿瘤]